|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000033346 |
|
最近更新日期: Date of Last Refreshed on: |
2020-05-28 22:52:09 |
|
注册时间: Date of Registration: |
2020-05-28 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
COVID-19感染者的红细胞沉降率 |
|
Public title: |
Erythrocyte Sedimentation Rate in COVID-19 Infections |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
感染病学 |
|
Scientific title: |
Infectious Diseases |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张伟 |
研究负责人: |
张伟 |
|
Applicant: |
Zhang Wei |
Study leader: |
Zhang Wei |
|
申请注册联系人电话: Applicant telephone: |
18985683936 |
研究负责人电话: Study leader's telephone: |
18982262419 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangwei_hxicu@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangwei_hxicu@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
贵州省遵义市大连路149号 |
研究负责人通讯地址: |
贵州省遵义市大连路149号 |
|
Applicant address: |
149 Dalian Road, Zunyi, Guizhou, China |
Study leader's address: |
149 Dalian Road, Zunyi, Guizhou, China |
|
申请注册联系人邮政编码: Applicant postcode: |
563000 |
研究负责人邮政编码: Study leader's postcode: |
563000 |
|
申请人所在单位: |
遵义医科大学附属医院 |
||
|
Applicant's institution: |
Affiliated Hospital of Zunyi Medical University |
||
|
研究负责人所在单位: |
遵义医科大学附属医院 |
||
|
Affiliation of the Leader: |
Affiliated Hospital of Zunyi Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KLL-2020-013 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
遵义医学院附属医院生物医学研究伦理委员会 |
||
|
Name of the ethic committee: |
The Biomedical Ethics of Affiliated Hospital of Zunyi Medical College |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-03-11 00:00:00 |
||
|
伦理委员会联系人: |
陈琦 |
||
|
Contact Name of the ethic committee: |
Qi Chen |
||
|
伦理委员会联系地址: |
贵州省遵义市大连路149号 |
||
|
Contact Address of the ethic committee: |
149 Dalian Road, Zunyi, Guizhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
遵义医科大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Hospital of Zunyi Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省遵义市大连路149号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
149 Dalian Road, Zunyi, Guizhou, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
贵州省科技厅科技支撑计划与贵州省科技厅重大基础研究计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
Department of Science and Technology of Support Plan in Guizhou Province and Department of Science and Technology of Fundamental Research Plan in Guizhou Province |
||||||||||||||||||||||
|
Target disease: |
新冠肺炎 |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
比较新冠肺炎患者血沉增快组与正常组之间的临床特征及流行病学特征之间的差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
To compare the clinical characteristics between the faster group and the normal group about erythrocyte sedimentation rate in COVID-19 patients, analyze the variables with significant differences, and explore the influencing factors of faster sedimentation rate. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
住院期间行血沉检测的COVID-19患者 |
||||||||||||||||||||||
|
Inclusion criteria |
COVID-19 patients with ESR during hospitalization |
||||||||||||||||||||||
|
排除标准: |
COVID-19住院期间未作ESR检测的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
COVID-19 patients without ESR during hospitalization |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-02-29 00:00:00至 To 2020-05-12 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-02-29 00:00:00 至 To 2020-05-12 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
No. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
当论文发表后在本试验平台发布试验数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
When our paper will be pulished in the journal, we are able to share our study data. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
我们的数据采集采用EXCEL表格手工录入。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Our clinical data were manually obtained from the Hospital Information System by researchers. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |